A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy. This phase 2 study explored the safety and efficacy of single-agent lenalidomide in previously untreated older AML patients with del(5q) who declined standard chemotherapy. Pa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Sekeres, Mikkael A., Gundacker, Holly, Lancet, Jeffrey, Advani, Anjali, Petersdorf, Stephen, Liesveld, Jane, Mulford, Deborah, Norwood, Tom, Willman, Cheryl L., Appelbaum, Frederick R., List, Alan F.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3142897/
https://ncbi.nlm.nih.gov/pubmed/21551228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-337303
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares